Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932409 · ClinicalTrials.gov registry record · Phase 1
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
A Phase 1 study of Endometrial Cancer, sponsored by University of Oklahoma.
- Active
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT03932409 is a Phase 1 study of Endometrial Cancer that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 45 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03932409, a Phase 1 study of Endometrial Cancer, is active but no longer recruiting, sponsored by University of Oklahoma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this single arm, open label study is to evaluate the feasibility of pembrolizumab combined with radiation administered to the upper part of the vagina (vaginal cuff brachytherapy) followed by three cycles of pembrolizumab and chemotherapy in patients with endometrial cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- RADIATION Vaginal cuff brachytherapy (VCB)
Study Locations (2)
Louisiana
- LSU Health New Orleans - New Orleans
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03932409
The ClinicalTrials.gov registry entry for NCT03932409 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (91% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03932409 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Louisiana, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT03932409 about?
NCT03932409 is a clinical study titled "Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer". The purpose of this single arm, open label study is to evaluate the feasibility of pembrolizumab combined with radiation administered to the upper part of the vagina (vaginal cuff brachytherapy) followed by three cycles of pembrolizumab and chemotherapy in patients with endometrial cancer.
What is the current status of trial NCT03932409?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2020-02-19. Estimated completion is 2026-09.
What conditions does trial NCT03932409 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT03932409?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), Vaginal cuff brachytherapy (VCB) (RADIATION).
Who is sponsoring clinical trial NCT03932409?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03932409 being conducted?
This trial has 2 study locations across Louisiana, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.